Rep. Pallone Seeks FDA Update On Imported Cosmetics; Input On Legislation Requested

The Democratic congressman from New Jersey requests updated data on imported cosmetics and FDA’s related inspection work in a June 26 letter to agency leadership, which follows a similar inquiry from Pallone in 2016. Further, he asks for any additional information that might inform the development of cosmetics reform legislation.

Capitol-building-dome-light

Rep. Frank Pallone, D-N.J., remains concerned about the safety of cosmetic products, asking the US Food and Drug Administration for an update on its imported cosmetic inspection activities and any additional input that could be useful in developing regulatory reform legislation.

Two years ago, FDA informed Pallone that less than 1% of the 2.9m cosmetics entering the US in fiscal 2016...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

Adcomm Reform: Getting Needed Information More Important Than Vote Or Discussion

 

US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

 

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.